Eupraxia Pharmaceuticals (EPRX) Stock Forecast & Price Target

Compare

36 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EPRX Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Eupraxia

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EPRX Stock 12 Month Forecast

Average Price Target

C$15.49

▲(90.53% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Eupraxia Pharmaceuticals in the last 3 months. The average price target is C$15.49 with a high forecast of C$19.55 and a low forecast of C$9.00. The average price target represents a 90.53% change from the last price of C$8.13.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"C$2","11":"C$11","20":"C$20","6.5":"C$6.5","15.5":"C$15.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19.55170728,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$19.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$15.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.5,11,15.5,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.5,9.35013132923077,10.200262658461538,11.050393987692308,11.900525316923076,12.750656646153846,13.600787975384616,14.450919304615384,15.301050633846152,16.151181963076922,17.001313292307692,17.851444621538462,18.701575950769232,{"y":19.55170728,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.5,9.037692307692307,9.575384615384616,10.113076923076923,10.650769230769232,11.188461538461539,11.726153846153846,12.263846153846153,12.801538461538462,13.33923076923077,13.876923076923077,14.414615384615384,14.952307692307691,{"y":15.49,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.5,8.538461538461538,8.576923076923077,8.615384615384615,8.653846153846153,8.692307692307692,8.73076923076923,8.76923076923077,8.807692307692308,8.846153846153847,8.884615384615385,8.923076923076923,8.961538461538462,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.96,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetC$19.55

Average Price TargetC$15.49

Lowest Price TargetC$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Albert Lowe

Craig-Hallum

C$16.76→C$19.55

Buy

140.49%

Upside

Reiterated

10/02/25

Craig-Hallum Remains a Buy on Eupraxia Pharmaceuticals (EPRX)

Gary Nachman

Raymond James

C$16.76

Buy

106.13%

Upside

Reiterated

10/02/25

Raymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)Eupraxia Pharmaceuticals announced encouraging new 4‐week data from Cohort 9 and reiterated a Strong Buy rating with a $12.00 target.

Brandon Folkes

H.C. Wainwright

C$16.76

Buy

106.13%

Upside

Reiterated

10/02/25

Promising Phase 2b Advancement of EP-104GI Boosts Buy Rating Amid Positive RESOLVE Trial ResultsValuation and Risks. We base our valuation on our probability-weighted clinical net present value discounted cash flow (DCF) model. We assign a 70% probability of success for EP-104GI, with peak sales in excess of $500M. We include risk-adjusted 2031E sales of $257M in our DCF, and assume a late 2028 or early 2029 launch for EP-104GI. Furthermore, we do not include any DiffuSphere platform technology value or the potential value from the EP-104OA (osteoarthritis program) program in our model, although we believe in the longer term both of these could unlock value beyond our current forecasts.

Kristen Kluska

Cantor Fitzgerald

C$15.36

Buy

88.96%

Upside

Reiterated

09/29/25

Eupraxia Pharmaceuticals (EPRX) Gets a Buy from Cantor Fitzgerald

Tania Armstrong-Whitworth

Canaccord Genuity

C$9

Buy

10.70%

Upside

Reiterated

09/02/25

Eupraxia Pharmaceuticals (EPRX) Gets a Buy from Canaccord Genuity

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Albert Lowe

Craig-Hallum

C$16.76→C$19.55

Buy

140.49%

Upside

Reiterated

10/02/25

Craig-Hallum Remains a Buy on Eupraxia Pharmaceuticals (EPRX)

Gary Nachman

Raymond James

C$16.76

Buy

106.13%

Upside

Reiterated

10/02/25

Brandon Folkes

H.C. Wainwright

C$16.76

Buy

106.13%

Upside

Reiterated

10/02/25

Kristen Kluska

Cantor Fitzgerald

C$15.36

Buy

88.96%

Upside

Reiterated

09/29/25

Eupraxia Pharmaceuticals (EPRX) Gets a Buy from Cantor Fitzgerald

Tania Armstrong-Whitworth

Canaccord Genuity

C$9

Buy

10.70%

Upside

Reiterated

09/02/25

Eupraxia Pharmaceuticals (EPRX) Gets a Buy from Canaccord Genuity

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eupraxia Pharmaceuticals

1 Month

xxx

Success Rate

2/4 ratings generated profit

Average Return

+4.98%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +4.98% per trade.

3 Months

xxx

Success Rate

4/4 ratings generated profit

Average Return

+13.80%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +13.80% per trade.

1 Year

Gary NachmanRaymond James

Success Rate

4/4 ratings generated profit

Average Return

+42.13%

reiterated a buy rating 4 days ago

Copying Gary Nachman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +42.13% per trade.

2 Years

xxx

Success Rate

4/4 ratings generated profit

Average Return

+42.13%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +42.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EPRX Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EPRX has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. EPRX average Analyst price target in the past 3 months is 15.49.

Each month's total comprises the sum of three months' worth of ratings.

EPRX Financial Forecast

EPRX Earnings Forecast

Next quarter’s earnings estimate for EPRX is -C$0.25 with a range of -C$0.34 to -C$0.13. The previous quarter’s EPS was -C$0.33. EPRX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year EPRX has Preformed in-line its overall industry.

No data currently available

EPRX Sales Forecast

Next quarter’s sales forecast for EPRX is C$0.00 with a range of C$0.00 to C$0.00. The previous quarter’s sales results were C$0.00. EPRX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year EPRX has Preformed in-line its overall industry.

EPRX Stock Forecast FAQ

What is TSE:EPRX’s average 12-month price target, according to analysts?

Based on analyst ratings, Eupraxia Pharmaceuticals’s 12-month average price target is 15.49.

What is TSE:EPRX’s upside potential, based on the analysts’ average price target?

Eupraxia Pharmaceuticals has 90.53% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TSE:EPRX a Buy, Sell or Hold?

Eupraxia Pharmaceuticals has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Eupraxia Pharmaceuticals’s price target?

The average price target for Eupraxia Pharmaceuticals is 15.49. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is C$19.55 ,the lowest forecast is C$9.00. The average price target represents 90.53% Increase from the current price of C$8.13.

What do analysts say about Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of TSE:EPRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Eupraxia Pharmaceuticals (EPRX) Stock Forecast & Price Target

EPRX Analyst Ratings

EPRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eupraxia Pharmaceuticals

EPRX Analyst Recommendation Trends

EPRX Financial Forecast

EPRX Earnings Forecast

EPRX Sales Forecast

EPRX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts